GOOD JENNIFER L
SEC CIK 1229245 · EDGAR
BoughtSold
Most active insiders at RYTM, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Lee Jennifer Kayden | EVP, Head of North America | — | $8.90M |
| 2 | Smith Hunter C | CFO | — | $8.84M |
| 3 | Mazabraud Yann | EVP, Head of International | — | $6.62M |
| 4 | Meeker David P | Pres, CEO, Dir | — | $5.13M |
| 5 | TETRAULT LYNN A. | Dir | — | $3.71M |
| 6 | Shulman Joseph | Chief Technical Off | — | $3.67M |
| 7 | Cramer Pamela J. | CHRO | — | $2.99M |
| 8 | German Christopher Paul | CAO, Corp. Ctrl | — | $930.9K |
| 9 | Garfield Alastair | CSO | — | $912.7K |
| 10 | Arbuckle Stuart A | Dir | — | — |
| 13 | GOOD JENNIFER L | Dir | — | — |
Transactions 19
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-06-25 18:01 | 2026-06-23 | RYTM | RHYTHM PHARMACEUTICALS, INC. | GOOD JENNIFER L | Dir | M - OptEx | — | +4,712 | 11.7K | +67% | — |
| D | 2025-06-23 | 2025-06-18 | RYTM | RHYTHM PHARMACEUTICALS, INC. | GOOD JENNIFER L | Dir | M - OptEx | — | +4,000 | 7,000 | +133% | — |
| D | 2025-03-25 | 2025-03-21 | TRVI | Trevi Therapeutics, Inc. | GOOD JENNIFER L | Pres, CEO, Dir | M - OptEx | $1.43 | +5,263 | 218.6K | +2% | +$7,526 |
| D | 2025-03-25 | 2025-03-21 | TRVI | Trevi Therapeutics, Inc. | GOOD JENNIFER L | Pres, CEO, Dir | S - Sale+OE | $6.58 | -5,263 | 213.3K | -2% | -$34.6K |
| D | 2024-09-19 | 2024-09-17 | RYTM | RHYTHM PHARMACEUTICALS, INC. | GOOD JENNIFER L | Dir | S - Sale+OE | $52.40 | -31.8K | 3,000 | -91% | -$1.66M |
| DM | 2024-09-19 | 2024-09-17 | RYTM | RHYTHM PHARMACEUTICALS, INC. | GOOD JENNIFER L | Dir | M - OptEx | $21.54 | +31.8K | 34.8K | +1,058% | +$684.1K |
| DM | 2024-09-11 | 2024-09-09 | RYTM | RHYTHM PHARMACEUTICALS, INC. | GOOD JENNIFER L | Dir | M - OptEx | $13.34 | +37.2K | 40.2K | +1,241% | +$496.7K |
| D | 2024-09-11 | 2024-09-09 | RYTM | RHYTHM PHARMACEUTICALS, INC. | GOOD JENNIFER L | Dir | S - Sale+OE | $50.45 | -37.2K | 3,000 | -93% | -$1.88M |
| DM | 2024-09-09 | 2024-09-06+ | TRVI | Trevi Therapeutics, Inc. | GOOD JENNIFER L | Pres, CEO, Dir | M - OptEx | $1.43 | +6,059 | 215.2K | +3% | +$8,664 |
| DM | 2024-09-09 | 2024-09-06+ | TRVI | Trevi Therapeutics, Inc. | GOOD JENNIFER L | Pres, CEO, Dir | S - Sale+OE | $3.03 | -6,059 | 213.3K | -3% | -$18.4K |
| DM | 2024-09-05 | 2024-09-03+ | TRVI | Trevi Therapeutics, Inc. | GOOD JENNIFER L | Pres, CEO, Dir | S - Sale+OE | $3.09 | -55.1K | 213.3K | -21% | -$170.1K |
| DM | 2024-09-05 | 2024-09-03+ | TRVI | Trevi Therapeutics, Inc. | GOOD JENNIFER L | Pres, CEO, Dir | M - OptEx | $1.43 | +55.1K | 217.2K | +34% | +$78.8K |
| DM | 2024-08-28 | 2024-08-26 | RYTM | RHYTHM PHARMACEUTICALS, INC. | GOOD JENNIFER L | Dir | M - OptEx | $18.63 | +14.5K | 17.5K | +484% | +$270.3K |
| D | 2024-08-28 | 2024-08-26 | RYTM | RHYTHM PHARMACEUTICALS, INC. | GOOD JENNIFER L | Dir | S - Sale+OE | $50.01 | -14.5K | 3,000 | -83% | -$725.5K |
| D | 2024-06-25 | 2024-06-21 | RYTM | RHYTHM PHARMACEUTICALS, INC. | GOOD JENNIFER L | Dir | M - OptEx | — | +3,000 | 3,000 | New | — |
| D | 2024-05-22 | 2024-05-20 | TRVI | Trevi Therapeutics, Inc. | GOOD JENNIFER L | Pres, CEO, Dir | M - OptEx | $2.19 | +25.0K | 238.3K | +12% | +$54.8K |
| D | 2024-05-22 | 2024-05-20 | TRVI | Trevi Therapeutics, Inc. | GOOD JENNIFER L | Pres, CEO, Dir | S - Sale+OE | $2.86 | -25.0K | 213.3K | -11% | -$71.6K |
| D | 2024-05-14 | 2024-05-10 | TRVI | Trevi Therapeutics, Inc. | GOOD JENNIFER L | Pres, CEO, Dir | S - Sale+OE | $2.90 | -4,578 | 213.3K | -2% | -$13.3K |
| D | 2024-05-14 | 2024-05-10 | TRVI | Trevi Therapeutics, Inc. | GOOD JENNIFER L | Pres, CEO, Dir | M - OptEx | $2.19 | +4,578 | 217.9K | +2% | +$10.0K |
Purchase Sale Sale after option exercise All abbreviations